| IV-01 Federico Amato Explainable Machine Learning prediction of edema adverse events in NSCLC patients treated with tepotinib Thursday 15:25-16:55 |
| IV-02 Enrique José Bandín Vilar Population pharmacokinetics of aripiprazole and its active metabolite dehydroaripiprazole in subjects receiving once-monthly intramuscular aripiprazole. Thursday 15:25-16:55 |
| IV-03 Bruna Bernar Dias PK/PD modelling of the effect of nanoencapsulated quetiapine on cortical dopamine concentrations in schizophrenia phenotyped rats Thursday 15:25-16:55 |
| IV-04 Divakar Budda Mu-opioid receptor binding of morphine and its main metabolites: impact of non-linear BBB transport of morphine. Thursday 15:25-16:55 |
| IV-05 Chao Chen Model-based meta-analysis of aggregate data on Parkinson’s disease clinical scores to inform future trial design Thursday 15:25-16:55 |
| IV-06 Lu Chen Posaconazole meta-PK analysis upon oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race Thursday 15:25-16:55 |
| IV-07 Alexandre Duong NONMEM versus nlmixr2 : An example of external evaluation of gentamicin Pop-PK models Thursday 15:25-16:55 |
| IV-08 Emma Eckernäs Optimizing infusion rates for N,N-dimethyltryptamine based on either a continuous variable model or a bounded integer model Thursday 15:25-16:55 |
| IV-09 Mehdi El Hassani Does sample size, sampling strategy, or handling of concentrations below the lower limit of quantification matter when externally evaluating population pharmacokinetic models? Thursday 15:25-16:55 |
| IV-10 Selma El Messaoudi Evaluation in model averaging: an application to viral dynamic models Thursday 15:25-16:55 |
| IV-11 Ibrahim El-Haffaf Model-informed precision dosing: can the administration method influence the predictive performance of a model? An example with piperacillin. Thursday 15:25-16:55 |
| IV-12 Raphaela Gessele How to inform a QSP model with gene expression data – exemplified with a model on intestinal epithelial integrity and RIPK2 inhibition Thursday 15:25-16:55 |
| IV-13 Sungwoo Goo Graph Diffusion Model to Understand Quantitative Systems Pharmacology Thursday 15:25-16:55 |
| IV-14 Farina Hellmann Population pharmacokinetic modeling of total active moiety exposure following doses of TV 46000, a long-acting subcutaneous risperidone injection Thursday 15:25-16:55 |
| IV-15 Niels Hendrickx Predicting individual disease progression including parameter uncertainty in rare neurodegenerative diseases: the example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS) Thursday 15:25-16:55 |
| IV-16 Jina Kim Proteolysis-Targeting Chimera (PROTAC) Design using Integrated Artificial Intelligence (AI) and Quantitative Systems Pharmacology (QSP) Model. Thursday 15:25-16:55 |
| IV-17 Jane Knöchel Using semi-mechanistic modelling to inform the design of the Ph3 program for a novel PCSK9 antisense oligonucleotide Thursday 15:25-16:55 |
| IV-18 Julia Korell Population Pharmacokinetic Model for BI 1015550 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis Thursday 15:25-16:55 |
| IV-19 Ryuji Kubota Developing SARS-CoV-2 viral dynamic model in patients with COVID-19 based on amount of viral RNA and viral titer Thursday 15:25-16:55 |
| IV-20 Shaun Kumar Empirical Population Pharmacodynamic Models for beti-cel for the Treatment of Patients with β-Thalassemia who Require Regular Transfusions. Thursday 15:25-16:55 |
| IV-21 Minji Kwon Optimization of dosing strategy for vancomycin using a population pharmacokinetic model combined with machine learning approaches Thursday 15:25-16:55 |
| IV-22 Mun Kyungran Development of User-Friendly Bayesian Predictive Platform for Blood Boron-10 Pharmacokinetics following Intravenous Infusion of [10B] L-4-BORONOPHENYLALANINE Thursday 15:25-16:55 |
| IV-23 Jennifer Lang Development of a semi-mechanistic pharmacokinetic/pharmacodynamic model of a small interfering RNA targeting liver proteins in mice and cynomolgus monkeys Thursday 15:25-16:55 |
| IV-24 Silvia Maria Lavezzi Sensitivity analysis of a two-state bacterial model for prediction of clinical short-term bactericidal efficacy in tuberculosis: GSK3036656 case study Thursday 15:25-16:55 |
| IV-25 Albin Leding Population pharmacokinetics of the antitubercular drug TBAJ587 and its two main metabolites Thursday 15:25-16:55 |
| IV-26 Hyunjung Lee External validation of population pharmacokinetic models on 7 published models of moxifloxacin-treated tuberculosis patients Thursday 15:25-16:55 |
| IV-27 Moon Hee Lee First-in-Human Dose Selection for TU7710 through Pharmacokinetic and Pharmacodynamic Modeling and Simulation Thursday 15:25-16:55 |
| IV-28 Giulia Lestini Population pharmacokinetics of KAF156/LUM-SDF and exposure-response analysis for the probability of cure for patients with uncomplicated malaria Thursday 15:25-16:55 |
| IV-29 Letao Li Preeclampsia increases maternal exposure to betamethasone in pregnancy: a population pharmacokinetic study Thursday 15:25-16:55 |
| IV-30 Letao Li Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: does inflammation play a role? Thursday 15:25-16:55 |
| IV-31 Hyeong-Seok Lim Translational pharmacokinetic-pharmacodynamic modeling and simulation to predict efficacious human doses for YH35324 (GI-301) Thursday 15:25-16:55 |
| IV-32 Klaus Lindauer Allometric Scaling for Efficacious First-in-Human Dose Prediction of Pharmacologically-Active Parent and Metabolite Based on Rat, Dog and Monkey PK data Thursday 15:25-16:55 |
| IV-33 Carolina Llanos-Paez Extended model-based meta-analysis of joint longitudinal FEV1 and exacerbation rate in randomized COPD trials Thursday 15:25-16:55 |
| IV-34 Jos Lommerse Building Effective Visualizations to Assess and Communicate Fit for Pharmacometric Models with Covariates (VACHETTE) Thursday 15:25-16:55 |
| IV-35 Servane Lunven Generative Models for Synthetic Data Generation: Application to PKPD data Thursday 15:25-16:55 |
| IV-36 Julia Macente Physiologically-based Pharmacokinetics modelling to predict the systemic exposure of medicines in infants via breastmilk: a contribution from the ConcePTION Project. Thursday 15:25-16:55 |
| IV-37 Wen Yao Mak Population pharmacokinetics and pharmacodynamics of eravacycline against pulmonary infections Thursday 15:25-16:55 |
| IV-38 Eleonora Marostica Population PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients Thursday 15:25-16:55 |
| IV-39 Sebastian Micluța-Câmpeanu Automatic model discovery in Quantitative Systems Biology Thursday 15:25-16:55 |
| IV-40 Yersultan Mirasbekov Characterizing Bootstrap Model Selection Variability Through an Automated Model Building Approach Thursday 15:25-16:55 |
| IV-41 Laurynas Mockeliunas Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development Thursday 15:25-16:55 |
| IV-42 Felix Müller Identification and quantification of variability in the microdialysis technique using mixed-effects modelling within an integrated in vitro and ex vivo approach: a linezolid case study. Thursday 15:25-16:55 |
| IV-43 Nina Nauwelaerts Physiologically Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to medicines: a contribution from the ConcePTION Project Thursday 15:25-16:55 |
| IV-45 Jacinta Nwogu Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites Thursday 15:25-16:55 |
| IV-46 Amaury O'Jeanson Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) combinations: should we monitor the BLI concentration? Thursday 15:25-16:55 |
| IV-47 Marije Otto Evaluation of Darigabat QTc Prolongation in Healthy Volunteers: a Concentration-QTcF Analysis Thursday 15:25-16:55 |
| IV-48 Agustos Cetin Ozbey Physiologically based pharmacokinetic modelling of the impact of hepatic impairment on glucuronidation – a case study with midazolam. Thursday 15:25-16:55 |
| IV-49 Seongwon Park Evidence-based evaluation for race difference of pirfenidone using population pharmacokinetics model |
| IV-50 Suemin Park Exposure-Response Analysis Using Time to Event Data for Bevacizumab Biosimilar, SB8 and the Reference Bevacizumab Thursday 15:25-16:55 |
| IV-51 Elena Pascual García Towards model-informed design of antibiotic therapies: understanding the impact of antibiotics on bacterial physiology & growth. Thursday 15:25-16:55 |
| IV-52 Blaise Pasquiers Rituximab in Anti‑Neutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis: population pharmacokinetic modeling and simulations of alternative doses in under-exposed patients Thursday 15:25-16:55 |
| IV-53 Christoph Pfaffendorf A combined population pharmacokinetic model of proguanil and its active metabolite cycloguanil in infants to adults with uncomplicated malaria Thursday 15:25-16:55 |
| IV-54 Anh Duc Pham Modelling rate and extent of resistance development against colistin in Klebsiella pneumoniae and Pseudomonas aeruginosa Thursday 15:25-16:55 |
| IV-55 Thao- Nguyen Pham Effect brain irradiation with X-ray/Proton beam on circulating immune cell in rodents: A longitudinal modeling approach Thursday 15:25-16:55 |
| IV-56 Morgane PHILIPP Impact of covariate model selection methods on covariate effects and their uncertainty in population pharmacokinetic analysis Thursday 15:25-16:55 |
| IV-57 Veshni Pillay-Fuentes Lorente Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites Thursday 15:25-16:55 |
| IV-58 Tim Preijers Dosing of convalescent plasma and hyperimmune anti-SARS-CoV-2 immunoglobulins: a phase I/II dose finding study Thursday 15:25-16:55 |
| IV-59 Fatiha Rachedi Predicting Motor function scores using uHex4 biomarker effect in Pompe disease Thursday 15:25-16:55 |
| IV-60 Christopher Rackauckas Robust Parameter Estimation of Rational Ordinary Differential Equations for NLME and QSP Thursday 15:25-16:55 |
| IV-61 Christopher Rackauckas Uncertainty quantified discovery of chemical reaction systems via Bayesian scientific machine learning Thursday 15:25-16:55 |
| IV-62 Ibtissem Rebai Evaluation of the Boruta Machine Learning Algorithm for Covariate Selection Thursday 15:25-16:55 |
| IV-63 Juan Eduardo Resendiz Galvan Pharmacokinetics of cycloserine in an Indian population with multidrug-resistant tuberculosis. Thursday 15:25-16:55 |
| IV-64 Gledys Reynaldo Fernandez Enlightenment the strategic selection of pegylated rHuEPO candidates using a mechanistic model- driven extrapolation approach of the pharmacokinetics and pharmacodynamics. Thursday 15:25-16:55 |
| IV-65 Karine Rodriguez-Fernandez Individualized dosing regimen optimization using a population pharmacokinetic-pharmacodynamic model for secukinumab in clinical practice psoriatic patients Thursday 15:25-16:55 |
| IV-67 Soroush Safaei Developing a PBPK/PD/Tox Modelling Framework for NANOBODY® Drug Conjugates Thursday 15:25-16:55 |
| IV-68 Medhat M. Said Disease-drug-drug interaction in drug repurposing of intravenous imatinib for COVID-19 ARDS Thursday 15:25-16:55 |
| IV-69 Eric Salgado Target engagement analysis of belimumab in patients with systemic lupus erythematosus (SLE) and primary Sjogren’s syndrome (pSS) Thursday 15:25-16:55 |
| IV-70 Louis Sandra Development of an indirect response model-based meta-analysis (MBMA) framework for the description of viral antigen decline for siRNA-based anti-HBV therapies Thursday 15:25-16:55 |
| IV-71 Darlene Santiago External Validation of Population PK and PD Models for Characterizing the Impact of CYP2C9 and VKORC1 Genotypes in the Management of Warfarin Therapy in Caribbean Hispanic Patients. Thursday 15:25-16:55 |
| IV-72 Maria Sanz Codina Evaluating ceftazidime-avibactam exposure in patients undergoing automated peritoneal dialysis using population pharmacokinetic modelling Thursday 15:25-16:55 |
| IV-73 Raphaël Saporta Translation of the in vitro antimicrobial activity of afabicin against Staphylococcus aureus to in vivo bacterial killing dynamics using a pharmacokinetic-pharmacodynamic model based on time-kill experiments Thursday 15:25-16:55 |
| IV-74 Sebastiaan Sassen The importance of model selection for a priori model informed precision dosing of vancomycin Thursday 15:25-16:55 |
| IV-75 Sharon Sawe Population pharmacokinetics of levofloxacin in South African adults treated for rifampicin-resistant tuberculosis. Thursday 15:25-16:55 |
| IV-76 Stef Schouwenburg A pooled population pharmacokinetic study of oral and intravenous clavulanic acid in neonates Thursday 15:25-16:55 |
| IV-77 Manna Semere Gebreyesus Population pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy Thursday 15:25-16:55 |
| IV-78 Marie Steinacker Non-linear autoregressive exogenous modelling to predict individual haematotoxicity during chemotherapy Thursday 15:25-16:55 |
| IV-79 Budi Octasari Susanto Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations Thursday 15:25-16:55 |
| IV-80 Carsten Terjung Modeling PK and PK/PD in of anti-VEGF agents in a preclinical rabbit model of VEGF-induced retinal hyperpermeability Thursday 15:25-16:55 |
| IV-81 Thi Quyen Tran Model-based meta-analysis of relationship between pioglitazone and histological outcomes in non-alcoholic steatohepatitis patients Thursday 15:25-16:55 |
| IV-82 Van Thuy Truong Combining PKPD models with agent-based modelling and reinforcement learning/artificial intelligence algorithm to optimize cancer treatment Thursday 15:25-16:55 |
| IV-83 Pieter Van Brantegem Longitudinal time to positivity is unable to predict clinical outcome for drug susceptible tuberculosis Thursday 15:25-16:55 |
| IV-84 Marinda van de Kreeke Interspecies scaling of host inflammatory response during infection Thursday 15:25-16:55 |
| IV-85 Coen van Hasselt Integrative pharmacokinetic model for esketamine and its metabolite esnorketamine Thursday 15:25-16:55 |
| IV-86 Wisse van Os Model-based comparison of antibiotic activity at target-site concentrations: a case study with ceftaroline and lefamulin for soft-tissue infections Thursday 15:25-16:55 |
| IV-87 Sander van Tilburg Population pharmacokinetics and pharmacodynamics of intravenous immunoglobulin treatment in patients with Guillain-Barré syndrome Thursday 15:25-16:55 |
| IV-88 Peter Velickovic Protocol optimization for the evaluation of pharmacokinetics, biomarkers and efficacy of antitubercular drugs in a novel tuberculosis infection model in marmosets Thursday 15:25-16:55 |
| IV-89 Diego Vera A translational semi-mechanistic pharmacokinetic-pharmacodynamic framework to design animal studies: Application to linezolid and vancomycin Thursday 15:25-16:55 |
| IV-90 Umberto Villani Model-based rationale for the in vitro characterisation of antimicrobial combinations in Buruli Ulcer Thursday 15:25-16:55 |
| IV-91 Thanakorn Vongjarudech Optimal longitudinal QT interval correction method considering changes in heart rate variability in patients treated for drug-resistant tuberculosis Thursday 15:25-16:55 |
| IV-92 My Luong Vuong Population pharmacokinetics of fluconazole in critically ill patients: an individual patient data meta-analysis. Thursday 15:25-16:55 |
| IV-93 Zhigang Wang A repeated time-to-event model linking infliximab clearance to the risk of relapse during maintenance treatment of patients with inflammatory bowel disease Thursday 15:25-16:55 |
| IV-94 Daichi Yamaguchi Population pharmacokinetic modelling for vancomycin using Bayesian model averaging approach Thursday 15:25-16:55 |
| IV-95 Shuying Yang Population dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia Thursday 15:25-16:55 |
| IV-96 Sung-yoon Yang Prediction of potential drug-drug interaction of tofacitinib and ritonavir using a population modeling approach with allometric scaling method Thursday 15:25-16:55 |
| IV-97 Janice Zhang Mechanism-based pharmacokinetic-pharmacodynamic modeling of short-term erythroferrone response and long-term efficacy of erythropoietin in chemotherapy-induced anemia rats Thursday 15:25-16:55 |
| IV-98 Qiaolin Zhao Paracetamol (Acetaminophen) and Metabolites Population Pharmacokinetics Model in children and adults with Spinal Muscular Atrophy Thursday 15:25-16:55 |
